Handelsavisen
prelaunch
Companies Basic Materials NVZMY.O
NV
NVZMY.O NASDAQ Chemicals

Novozymes A/S

$63,50
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
26,2B USD
P/E
EV / Rev
Div yield
1,61 %
Op margin
19,6 %
ROE
5,4 %
Net margin
14,0 %
Debt / equity
0,28
Beta
52w range
Volume
Day range
Prev close
$61,46
Open
Next earnings
Ex-dividend
TR 1Y
About

Novozymes A/S operates in the Materials sector, specifically within the Chemicals industry, generating revenue through its core chemical activities.

Business. Novozymes A/S (NVZMY.O) is a Danish company operating in the chemicals industry within the materials sector. The firm is headquartered in Denmark and is listed on the NASDAQ exchange. Specific details regarding its operating segments and geographic revenue mix are not provided in the available data.

Classification85 %
SectorMaterials
Industry groupChemicals
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
PNC Investments LLC
largest disclosed fund holder
Profitability
5,4 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning NVZMY.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials · THIS SECTOR+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,7 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,4 %−2,7 %−0,9 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Consumer Staples−0,7 %+2,3 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to NVZMY.O. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR
    • Congressional trades
    • CongressJosh Gottheimer — Novozymes A/S Unsponsored2023-10-16 · Democrat · NJ · Purchase · $1,001 - $15,000
    • CongressJosh Gottheimer — Novozymes A/S Unsponsored2023-09-15 · Democrat · NJ · Sale · $1,001 - $15,000

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Novozymes A/S (NVZMY.O) is a Danish company operating in the chemicals industry within the materials sector. The firm is headquartered in Denmark and is listed on the NASDAQ exchange. Specific details regarding its operating segments and geographic revenue mix are not provided in the available data.

    Classification85 %
    SectorMaterials
    Industry groupChemicals
    AI synthesis
    GENERATED

    Novozymes A/S maintains a capital structure characterized by a debt-to-equity ratio of 0.28 and a current ratio of 0.72. The balance sheet reflects total assets of 16.35 billion EUR against total liabilities of 5.49 billion EUR, resulting in total equity of 10.86 billion EUR. Long-term debt stands at 3.01 billion EUR, while cash and equivalents are limited to 275.3 million EUR. This results in a negative net cash position, as total debt exceeds liquid assets. The company generates operating cash flow of 1.22 billion EUR, but free cash flow is constrained to 284.9 million EUR due to capital expenditures of 470.8 million EUR.

    Profitability metrics indicate a return on equity of 5.38% and a return on assets of 3.57%. The company reports a gross profit of 2.24 billion EUR on revenue of 4.16 billion EUR, yielding an operating income of 816.7 million EUR and net income of 583.6 million EUR. The valuation multiples reflect a price-to-earnings ratio of 43.44, a price-to-book ratio of 2.34, and an EV/EBITDA of 34.38. The EV/Revenue multiple is 6.75. These returns and multiples must be viewed in the context of the broader Chemicals industry, though specific cohort median comparisons are not provided in the current data set.

    Revenue concentration and geographic exposure details are not explicitly broken down in the available segment or geography sections. The company’s activity is broadly defined as Chemicals within the Materials sector. Without specific segment revenue data, the analysis relies on the aggregate financial performance of the entire entity. The lack of granular segment data limits the ability to assess specific growth drivers or regional risks within the portfolio.

    Growth trajectory analysis is constrained by the absence of historical period data in the input. The current financial snapshot provides a single-period view of revenue at 4.16 billion EUR and net income at 583.6 million EUR. Without multi-year annual or quarterly trends, it is not possible to calculate year-over-year growth rates or assess the consistency of revenue expansion. The analysis therefore focuses on the current period's absolute performance and valuation metrics.

    Risk assessment indicates medium liquidity risk and low dilution risk. A key flag notes that net cash is negative after subtracting total debt, highlighting a reliance on debt financing relative to liquid reserves. The current ratio of 0.72 suggests potential short-term liquidity pressure, as current liabilities exceed current assets. However, the low dilution risk implies that share count stability is maintained, with basic and diluted shares outstanding both at 412.5 million.

    Recent observations include a market capitalization reference of approximately 25.44 billion USD and a workforce of 11,641 employees as of 2025-12-31. The company is headquartered in Denmark and was incorporated on 2000-11-13. ESG pillar scores indicate a controversies score of 100, governance of 36, and social of 75. News event observations contain technical failure logs related to data processing ("failed_redrive") rather than substantive corporate events, indicating no significant recent public disclosures or news triggers in the provided data.

    Key takeaways
    • Novozymes trades at a high P/E of 43.44 and EV/EBITDA of 34.38, suggesting premium valuation expectations.
    • Liquidity is constrained with a current ratio of 0.72 and negative net cash position due to 3.01 billion EUR in long-term debt.
    • Profitability is modest with ROE of 5.38% and ROA of 3.57%, driven by 583.6 million EUR net income on 4.16 billion EUR revenue.
    • Free cash flow is limited to 284.9 million EUR after 470.8 million EUR in capital expenditures.
    • Dilution risk is low with stable share count, but liquidity risk is medium due to short-term coverage ratios.
    • No historical growth data or segment breakdowns are available to assess trend consistency or revenue concentration.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $63,50
    Market cap
    $25.35B
    Enterprise value
    $28.08B
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    23.0x
    P / B
    2.3x
    P / Tangible book
    2.3x
    Tangible book
    $10.86B
    Net cash
    -$2.73B
    Current ratio
    0.7
    Debt / equity
    0.3
    ROA
    3.6%
    ROE
    5.4%
    Cash conversion
    209.0%
    CapEx / revenue
    -11.3%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution3 analysts
    Strong buy2
    Buy0
    Hold1
    Sell0
    Strong sell0
    12-month price target$76,34 · Median $74,00
    Low $72,01High $83,00
    Operating income · consensus1,2B EUR
    EPS surprise
    −27,3 %
    reported vs consensus · miss
    Revenue surprise
    +0,4 %
    reported vs consensus · beat

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin19,6 %Above P75
    Net Margin14,0 %Above P75
    ROE5,4 %Above median
    Capex / Rev-11,3 %Below median
    D/E0,28Above median
    Cash Conv2,09Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Reference data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Price To Tangible Book
      market_price / (tangible_book_value / shares_outstanding_diluted)
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Return On Equity
      net_income / total_equity
    • Enterprise Value
      market_cap - net_cash
    • Ev To Revenue
      enterprise_value / revenue
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    Source documents
    • Novozymes A/S Market data — financials · 2026-07-28
    • failed_redrive (failed_redrive) on NVZMY.O · 2026-07-28
    • Novozymes A/S — company reference export (2026-07-05) · 2026-07-28

    Ownership & reference

    Top holders

    • PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$0M

    Insider activity

    — missing data

    Short positioning

    26.6Kshares short+87.2% vs prior
    1days to cover
    3.2Kfails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    NVZMY.PKCanonical
    NASDAQ · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2023-11-07CONGRESSJosh Gottheimer (house) purchase shares → $1,001 - $15,000
    2023-10-11CONGRESSJosh Gottheimer (house) sale shares → $1,001 - $15,000
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Reference data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage